Amneal Pharmaceuticals, Inc. (AMRX)

NASDAQ: AMRX · Real-Time Price · USD

13.17

+0.22 (1.70%)

At close: May 29, 2026, 4:00 PM EDT

13.01

-0.16 (-1.21%)

After-hours: May 29, 2026, 7:41 PM EDT

Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Affordable Medicines Net Revenue	1.75B	1.75B	1.69B
Affordable Medicines Net Revenue Growth	0.49%	3.58%	14.53%
Specialty Net Revenue	553.48M	528.51M	445.75M
Specialty Net Revenue Growth	4.72%	18.57%	14.16%
AvKARE Net Revenue	738.33M	744.73M	662.95M
AvKARE Net Revenue Growth	-0.86%	12.34%	24.67%
Revenue (Other)	4.00K	4.00K	6.00K
Revenue (Total)	3.05B	3.02B	2.79B
Revenue (Total) Growth	0.90%	8.05%	16.73%

Gross Profit

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Affordable Medicines Gross Profit	702.64M	683.92M	673.90M
Affordable Medicines Gross Profit Growth	2.74%	1.49%	20.87%
Specialty Gross Profit	317.62M	282.59M	242.93M
Specialty Gross Profit Growth	12.40%	16.33%	37.89%
AvKARE Gross Profit	157.26M	146.79M	103.61M
AvKARE Gross Profit Growth	7.13%	41.68%	19.29%
Gross Profit (Other)	-	2.00K	2.00K
Gross Profit (Total)	1.18B	1.11B	1.02B
Gross Profit (Total) Growth	5.77%	9.10%	24.36%

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Affordable Medicines Operating Income	390.95M	380.80M	270.10M
Affordable Medicines Operating Income Growth	2.67%	40.98%	-2.20%
Specialty Operating Income	151.07M	116.00M	113.58M
Specialty Operating Income Growth	30.23%	2.13%	73.94%
AvKARE Operating Income	93.10M	83.62M	42.90M
AvKARE Operating Income Growth	11.35%	94.90%	36.14%
Corporate and Other Operating Income	-199.60M	-186.32M	-177.26M
Operating Income (Total)	435.52M	394.10M	249.33M
Operating Income (Total) Growth	10.51%	58.06%	22.00%

Updated May 7, 2026. Data Source: Fiscal.ai.